1.Activities of Biapenem against Mycobacterium tuberculosis in Macrophages and Mice.
Zhen Yong GUO ; Wei Jie ZHAO ; Mei Qin ZHENG ; Shuo LIU ; Chen Xia YAN ; Peng LI ; Shao Fa XU
Biomedical and Environmental Sciences 2019;32(4):235-241
OBJECTIVE:
To assess the activities of biapenem against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis.
METHODS:
Biapenem/clavulanate (BP/CL) was evaluated for in vitro activity against Mycobacterium tuberculosis (Mtb) multidrug-resistant (MDR) isolates, extensively drug-resistant (XDR) isolates, and the H37RV strain. BP/CL activity against the H37Rv strain was assessed in liquid cultures, in macrophages, and in mice..
RESULTS:
BP/CL exhibited activity against MDR and XDR Mtb isolates in liquid cultures. BP/CL treatment significantly reduced the number of colony forming units (CFU) of Mtb within macrophages compared with control untreated infected macrophages. Notably, BP/CL synergized in pairwise combinations with protionamide, aminosalicylate, and capreomycin to achieve a fractional inhibitory concentration for each pairing of 0.375 in vitro. In a mouse tuberculosis infection model, the efficacy of a cocktail of levofloxacin + pyrazinamide + protionamide + aminosalicylate against Mtb increased when the cocktail was combined with BP/CL, achieving efficacy similar to that of the positive control treatment (isoniazid + rifampin + pyrazinamide) after 2 months of treatment.
CONCLUSION
BP/CL may provide a new option to clinically treat MDR tuberculosis.
Animals
;
Anti-Infective Agents
;
pharmacology
;
therapeutic use
;
Cell Line
;
Drug Evaluation, Preclinical
;
Macrophages
;
Mice
;
Mycobacterium tuberculosis
;
drug effects
;
Thienamycins
;
pharmacology
;
therapeutic use
;
Tuberculosis, Multidrug-Resistant
;
drug therapy
2.The First Case of Septicemia Caused by Imipenem-Susceptible, Meropenem-Resistant Klebsiella pneumoniae.
Shizuo KAYAMA ; Norifumi SHIGEMOTO ; Ryuichi KUWAHARA ; Takashi ISHINO ; Kentaro IMON ; Makoto ONODERA ; Michiya YOKOZAKI ; Hiroki OHGE ; Motoyuki SUGAI
Annals of Laboratory Medicine 2013;33(5):383-385
No abstract available.
Aged
;
Drug Resistance, Bacterial
;
Humans
;
Imipenem/pharmacology/therapeutic use
;
Klebsiella Infections/diagnosis/drug therapy/*microbiology
;
Klebsiella pneumoniae/drug effects/isolation & purification/*physiology
;
Male
;
Microbial Sensitivity Tests
;
Phenotype
;
Sepsis/diagnosis/drug therapy/*microbiology
;
Thienamycins/pharmacology/therapeutic use
3.First Detection of VIM-4 Metallo-beta-Lactamase-Producing Citrobacter freundii in China.
Annals of Laboratory Medicine 2013;33(1):84-85
No abstract available.
Aged
;
Anti-Bacterial Agents/pharmacology/therapeutic use
;
Cefotaxime/therapeutic use
;
China
;
Ciprofloxacin/therapeutic use
;
Citrobacter freundii/drug effects/*enzymology/isolation & purification
;
Drug Resistance, Multiple, Bacterial
;
Humans
;
Imipenem/pharmacology
;
Male
;
Microbial Sensitivity Tests
;
Respiratory Tract Infections/*diagnosis/drug therapy/microbiology
;
Thienamycins/pharmacology
;
beta-Lactamases/*metabolism
4.Two Cases of Vancomycin-intermediate Staphylococcus aureus Isolated from Joint Tissue or Wound.
Ki Ho HONG ; Jeong Su PARK ; Eui Chong KIM
The Korean Journal of Laboratory Medicine 2008;28(6):444-448
Since its first isolation in 1997, vancomycin-intermediate Staphylococcus aureus (VISA) has been a clinical concern because it may lead to treatment failure. Up to the present, there were two reports of clinical VISA cases in Korea. We now report two additional cases of VISA with the minimum inhibitory concentration (MIC) of 4 microgram/mL. The first patient was a 59 yr-old man who had undergone total hip replacement arthroplasty in 1999 due to avascular necrosis of femur heads. He had recurrent episodes of infected hip caused by methicillin-resistant Staphylococcus aureus (MRSA) and was treated with vancomycin. He underwent replacement operation of prosthesis. Cultures of joint fluid and joint tissue grew S. aureus. Vancomycin MIC as determined by a broth microdilution method was 4 microgram/mL for the both isolates. The patient was treated with high enough doses of vancomycin to maintain serum trough concentrations at 20-25 microgram/mL for 52 days and was discharged. The second patient was a 57 yr-old man with diabetes. He lost consciousness from drinking. After recovery of consciousness, he was diagnosed with aspiration pneumonia. MRSA and Acinetobacter baumannii were cultured from sputum and the patient was treated with vancomycin and meropenem. During hospitalization, bed sores developed in his ankle and back. A wound culture from the sore grew S. aureus with vancomycin MIC of 4 microgram/mL. Since infection was localized, systemic antibiotics did not seem necessary, and the patient was transferred to another hospital for isolation and management.
Acinetobacter Infections/drug therapy
;
Acinetobacter baumannii/isolation & purification
;
Anti-Bacterial Agents/pharmacology/*therapeutic use
;
Humans
;
Joints/microbiology
;
Male
;
Methicillin-Resistant Staphylococcus aureus/*isolation & purification
;
Microbial Sensitivity Tests
;
Middle Aged
;
Pressure Ulcer/microbiology
;
Staphylococcal Infections/*drug therapy
;
Thienamycins/pharmacology/therapeutic use
;
Vancomycin/pharmacology/*therapeutic use
;
*Vancomycin Resistance